Literature DB >> 21337672

Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis.

Sharon D'Mello1, Anna Trauernicht, Anne Ryan, Erin Bonkowski, Tara Willson, Bruce C Trapnell, Stuart J Frank, Subra Kugasathan, Lee A Denson.   

Abstract

BACKGROUND: Growth failure remains a common complication of pediatric Crohn's disease (CD) and has been associated with small bowel involvement and need for surgery. We have reported that patients with elevated (≥ 1.6 μg/mL) granulocyte macrophage colony stimulating factor autoantibodies (GM-CSF Ab) are more likely to experience complicated ileal disease requiring surgery. We hypothesized that concurrent GM-CSF Ab and CARD15 risk allele carriage (C15(+) GMAb(+) ) would be associated with growth failure in CD and growth hormone (GH) resistance in murine ileitis.
METHODS: We enrolled 229 pediatric CD patients at two sites and determined CARD15 genotype, serum GM-CSF Ab, and GH binding protein (GHBP), and height (HTz) and weight (WTz) z-scores at diagnosis. Ileitis was induced in card15-deficient mice by GM-CSF neutralization and nonsteroidal antiinflammatory drug (NSAID) exposure. Hepatic GH receptor (GHR) abundance and GH-dependent Stat5 activation were determined by western blot and Igf-I mRNA expression by real-time polymerase chain reaction (PCR).
RESULTS: Mean (95% confidence interval [CI]) HTz at diagnosis was reduced to -0.48 (-4.2, 2.3) in C15(+) GMAb(+) patients, compared to -0.07 (-4.9, 3.4) in disease controls (P ≤ 0.05). Circulating GHBP, as a marker for tissue GHR abundance, was reduced in C15(+) GMAb(+) patients. Hepatic GHR abundance, GH induction of Stat5 tyrosine phosphorylation, and Igf-I mRNA expression were reduced in male card15-deficient mice with ileitis due to GM-CSF neutralization and NSAID exposure.
CONCLUSIONS: Innate dysfunction due to concurrent genetic variation in CARD15 and neutralizing GM-CSF Ab is associated with linear growth failure in pediatric CD, and hepatic GH resistance in murine ileitis.
Copyright © 2011 Crohn's & Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21337672      PMCID: PMC3057426          DOI: 10.1002/ibd.21689

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

1.  Adult height in patients with early onset of Crohn's disease.

Authors:  A Sawczenko; A B Ballinger; N M Croft; I R Sanderson; M O Savage
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 2.  Growth hormone binding protein 2001.

Authors:  G Baumann
Journal:  J Pediatr Endocrinol Metab       Date:  2001-04       Impact factor: 1.634

3.  Growth and clinical course of children with Crohn's disease.

Authors:  A M Griffiths; P Nguyen; C Smith; J H MacMillan; P M Sherman
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

4.  TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding.

Authors:  L A Denson; R K Menon; A Shaufl; H S Bajwa; C R Williams; S J Karpen
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

5.  High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.

Authors:  Kanji Uchida; Koh Nakata; Bruce C Trapnell; Takahiro Terakawa; Emi Hamano; Ayako Mikami; Ikumi Matsushita; John F Seymour; Masayoshi Oh-Eda; Ikuo Ishige; Yoshinobu Eishi; Takayuki Kitamura; Yoshitsugu Yamada; Kazuo Hanaoka; Naoto Keicho
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

6.  Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis.

Authors:  F De Benedetti; C Meazza; M Oliveri; P Pignatti; M Vivarelli; T Alonzi; E Fattori; S Garrone; A Barreca; A Martini
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

7.  Hormone and receptor studies: relationship to linear growth in childhood and puberty.

Authors:  T J Merimee; B Russell; S Quinn; W Riley
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

8.  Nutritional status and growth hormone-binding protein.

Authors:  M C Postel-Vinay; C Saab; M Gourmelen
Journal:  Horm Res       Date:  1995

9.  NOD2/CARD15 variants are associated with lower weight at diagnosis in children with Crohn's disease.

Authors:  Gitit Tomer; Clare Ceballos; Erlinda Concepcion; Keith J Benkov
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

10.  Longitudinal growth in children and adolescents with inflammatory bowel disease.

Authors:  H Hildebrand; J Karlberg; B Kristiansson
Journal:  J Pediatr Gastroenterol Nutr       Date:  1994-02       Impact factor: 2.839

View more
  7 in total

Review 1.  Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors.

Authors:  Sarah F Bortvedt; P Kay Lund
Journal:  Curr Opin Gastroenterol       Date:  2012-03       Impact factor: 3.287

Review 2.  Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains.

Authors:  Mark D DeBoer; Lee A Denson
Journal:  J Pediatr       Date:  2013-03-22       Impact factor: 4.406

Review 3.  Crohn's disease and growth deficiency in children and adolescents.

Authors:  Marco Gasparetto; Graziella Guariso
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

4.  Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis.

Authors:  Jessica Connors; Sana Basseri; Amy Grant; Nick Giffin; Gamal Mahdi; Angela Noble; Mohsin Rashid; Anthony Otley; Johan Van Limbergen
Journal:  J Crohns Colitis       Date:  2017-09-01       Impact factor: 9.071

Review 5.  Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer.

Authors:  Ferenc Sipos; Hajnal Székely; Imre Dániel Kis; Zsolt Tulassay; Györgyi Műzes
Journal:  World J Gastroenterol       Date:  2017-12-14       Impact factor: 5.742

6.  Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease.

Authors:  Hye-Young Jin; Jae-Sang Lim; Yena Lee; Yunha Choi; Seak-Hee Oh; Kyung-Mo Kim; Han-Wook Yoo; Jin-Ho Choi
Journal:  BMC Pediatr       Date:  2021-01-14       Impact factor: 2.125

Review 7.  Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.

Authors:  Mabrouka A Altowati; Richard K Russell; S Faisal Ahmed
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.